Authors

Rupesh Kotecha, Miami Cancer InstituteFollow

Keynote B36: Open-label study of first-line tumor treating fields (150kHz) plus pembrolizumab for non-small cell lung cancer

Publication Date

8-6-2022

Presented At:

IASLC 2022 World Conference on Lung Cancer

Content Type

Poster

Additional Authors:

Additional authors and institutional affiliations

Citation

Kotecha, Rupesh, "Keynote B36: Open-label study of first-line tumor treating fields (150kHz) plus pembrolizumab for non-small cell lung cancer" (2022). All Publications. 4702.
https://scholarlycommons.baptisthealth.net/se-all-publications/4702